FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Tomoyuki Handa

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Survival Rate

Co-author Network

Publications

TOP 3
Honoka Arai; Tomoyuki Handa; Kazuhiro Maki; Yuko Nakamura; Ko Sasaki; Jiro Tadokoro; Shigeharu Tsurumi; Kinuko Mitani
[CD20-positive peripheral T-cell lymphoma, not otherwise specified].
Wataru Takahashi; Katsuya Tokita; Shigeharu Tsurumi; Yuko Nakamura; Ko Sasaki; Jiro Tadokoro; Honoka Arai; Tomoyuki Handa; Hisako Iso; Kazuhiro Maki; Kinuko Mitani
[CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].
Tomoyuki Handa; Yukihiro Arai; Kinuko Mitani
[Myelodysplastic syndrome associated with intestinal tract-type Behçet disease characterized by an esophageal ulcer].

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Tomoyuki Handa (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Honoka Arai; Tomoyuki Handa; Kazuhiro Maki; Yuko Nakamura; Ko Sasaki; Jiro Tadokoro; Shigeharu Tsurumi; Kinuko Mitani
[CD20-positive peripheral T-cell lymphoma, not otherwise specified].
[Rinshō ketsueki] The Japanese journal of clinical hematology 2012;53(7):705-9.
2012: Wataru Takahashi; Katsuya Tokita; Shigeharu Tsurumi; Yuko Nakamura; Ko Sasaki; Jiro Tadokoro; Honoka Arai; Tomoyuki Handa; Hisako Iso; Kazuhiro Maki; Kinuko Mitani
[CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].
[Rinshō ketsueki] The Japanese journal of clinical hematology 2012;53(1):71-7.
2004: Tomoyuki Handa; Yukihiro Arai; Kinuko Mitani
[Myelodysplastic syndrome associated with intestinal tract-type Behçet disease characterized by an esophageal ulcer].
[Rinshō ketsueki] The Japanese journal of clinical hematology 2004;45(10):1135-7.
2004: Yukihiro Arai; Tomoyuki Handa; Kinuko Mitani
[Adult-onset Still disease presenting with disseminated intravascular coagulation].
[Rinshō ketsueki] The Japanese journal of clinical hematology 2004;45(4):316-8.
2004: Fumihiko Nakamura; Yuui Kishimoto; Tomoyuki Handa; Yukihiro Arai; Kinuko Mitani
Myelodysplastic syndrome with central diabetes insipidus manifesting hypodipsic hypernatremia and dehydration.
American journal of hematology 2004;75(4):213-6.
2003: Yuko Nakamura; Yukihiro Arai; Hisako Gunji; Honoka Arai; Fumihiko Nakamura; Tomoyuki Handa; Jiro Tadokoro; Kinuko Mitani
[Hypereosinophilic syndrome developing after prednisolone therapy for autoimmune hemolytic anemia].
[Rinshō ketsueki] The Japanese journal of clinical hematology 2003;44(11):1117-9.
2002: Yuko Nakamura; Yukihiro Arai; Hisako Gunji; Honoka Arai; Fumihiko Nakamura; Tomoyuki Handa; Jiro Tadokoro; Kazuhiro Maki; Kenji Saito; Kinuko Mitani
[WT1 gene expression in patients with acute myelogenous leukemia or high risk myelodysplastic syndrome successfully treated with the CAG regimen].
[Rinshō ketsueki] The Japanese journal of clinical hematology 2002;43(10):960-2.
2002: Yukihiro Arai; Tomoyuki Handa; Fumihiko Nakamura; Wataru Takahashi; Kazuhiro Maki; Kinuko Mitani
[Double t (3; 21) in acute myelomonocytic leukemia transformed from chronic myelomonocytic leukemia].
[Rinshō ketsueki] The Japanese journal of clinical hematology 2002;43(9):865-7.
2001: Jiro Tadokoro; Hisako Gunji; Tomoyuki Handa; M Aoyagi; Yuichi Nakamura; Kenji Saito; Shinpei Furusawa
[Primary renal non-Hodgkin's lymphoma presenting as immune thrombocytopenia].
[Rinshō ketsueki] The Japanese journal of clinical hematology 2001;42(1):41-6.
2000: Tomoyuki Handa; K Yamamoto; Jiro Tadokoro; Y Kikkawa; Shigeharu Tsurumi; Yuichi Nakamura; Kenji Saito; Y Uzuka; Y Saito; Shinpei Furusawa
[CD19-positive acute myeloblastic leukemia developed 12 years after the onset of hypereosinophilic syndrome].
[Rinshō ketsueki] The Japanese journal of clinical hematology 2000;41(9):723-8.
2000: Kenji Saito; Y Nakamura; M Aoyagi; Kazuo Waga; K Yamamoto; Arina Aoyagi; F Inoue; Yuichi Nakamura; Yukihiro Arai; Jiro Tadokoro; Tomoyuki Handa; Shigeharu Tsurumi; Honoka Arai; Y Kawagoe; H Gunnji; Y Kitsukawa; Wataru Takahashi; Shinpei Furusawa
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
International journal of hematology 2000;71(3):238-44.